Brace Pharma Capital

Brace Pharma Capital is a strategic investment company formed by EMS S/A, the largest pharmaceutical company in Brazil, and high net worth biotech investors. The firm specializes in investing in innovative, life-changing therapies for diseases with a high degree of unmet medical need and insufficient treatment options. Their portfolio includes companies like Avidity Biosciences, AVROBIO, Precision Biosciences, Zymeworks, Antiva Biosciences, F2G, Gliknik, Navitor Pharmaceuticals, ReViral, Turnstone Biologics, and Vero Biotech.

The company's investment strategy focuses on clinical-stage projects with the potential to reach the market within 3-5 years, and pre-clinical stage projects with predictive animal models aiming for market entry in 5-7 years. They prefer disease-modifying treatments for debilitating orphan diseases and target U.S. market potential exceeding $200 million in revenue. Brace Pharma Capital seeks to partner with companies that have highly experienced management teams and well-defined, FDA-validated clinical efficacy endpoints.

Brace Pharma Capital's portfolio showcases a commitment to advancing therapies across various stages of development, from early-stage innovations to late-stage clinical trials. Their investments span multiple therapeutic areas, including oncology, infectious diseases, and rare genetic disorders, reflecting a broad approach to addressing unmet medical needs in the healthcare sector.